VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 89 filers reported holding VERONA PHARMA PLC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,821,407 | -20.0% | 4,467,571 | +3.8% | 0.02% | -11.8% |
| Q2 2023 | $90,971,825 | +37.6% | 4,303,303 | +30.7% | 0.02% | +30.8% |
| Q1 2023 | $66,092,778 | -24.4% | 3,291,473 | -1.6% | 0.01% | -27.8% |
| Q4 2022 | $87,440,649 | +104.8% | 3,346,370 | -19.9% | 0.02% | +100.0% |
| Q3 2022 | $42,691,000 | +166.2% | 4,177,276 | +9.1% | 0.01% | +200.0% |
| Q2 2022 | $16,039,000 | -14.9% | 3,828,149 | +1.3% | 0.00% | 0.0% |
| Q1 2022 | $18,856,000 | -41.9% | 3,778,785 | -21.8% | 0.00% | -40.0% |
| Q4 2021 | $32,470,000 | +38.0% | 4,831,988 | +12.5% | 0.01% | +25.0% |
| Q3 2021 | $23,531,000 | -8.0% | 4,294,038 | +9.8% | 0.00% | 0.0% |
| Q2 2021 | $25,584,000 | -19.4% | 3,911,840 | +3.0% | 0.00% | -33.3% |
| Q1 2021 | $31,753,000 | +264.1% | 3,798,141 | +204.9% | 0.01% | +200.0% |
| Q4 2020 | $8,720,000 | – | 1,245,699 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |